ArticleDEN open2027
Clinical Outcomes of Antrectomy for Patients With Multiple Type I Gastric Neuroendocrine Tumors: A Case Series.
Article in DEN open, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Type I gastric neuroendocrine tumors (T1-GNETs) are frequently associated with autoimmune gastritis and typically present as multiple lesions. The treatment options for T1-GNETs include endoscopic resection (ER), surgical resection, and pharmaceutical therapies. Antrectomy is reportedly an effective treatment for multiple T1-GNETs; however, its efficacy and indication remain unclear. In this study, we aimed to assess the efficacy of antrectomy in patients with multiple T1-GNETs. Methods: We retrospectively evaluated the clinical outcomes of eight patients with persistent multiple T1-GNETs in the gastric remnant following antrectomy from 2005 to 2023. Results: All eight patients (median age: 60 years, male-to-female ratio 1:3) had body-dominant atrophic gastritis. Median preoperative serum gastrin levels were 4800 (range, 2400-11,000) pg/mL. Preoperative endoscopy revealed <10 in two, 10-20 in one, and >20 in five patients. Antrectomy was performed as a primary surgery in three patients, as a completion surgery following non-curative ER in two patients, and a combination therapy with pre-antrectomy ER in three patients. Median serum gastrin levels decreased to 68 (range, 25-120) pg/mL during the median followup of 56 (range, 14-72 months). Tumor regression was observed in two patients and disappearance in six, with no recurrence or deaths. Conclusion: We assessed the residual T1‑GNETs post-antrectomy and discovered either regression or disappearance in all cases. Normalized serum gastrin levels following antrectomy may have contributed to this outcome. On the basis of our findings, the combination of antrectomy and ER resulted in tumor regression that may represent a potential organ-preserving approach for patients with multiple T1-GNETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.